Patents by Inventor Elliott Richelson
Elliott Richelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7671025Abstract: This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist in combination with an opioid receptor agonist also are provided.Type: GrantFiled: February 23, 2007Date of Patent: March 2, 2010Assignees: Sarentis Therapeutics, Inc., Mayo Foundation for Medical Education and ResearchInventors: Denise Barbut, Elliott Richelson
-
Patent number: 7642231Abstract: The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.Type: GrantFiled: June 14, 2006Date of Patent: January 5, 2010Assignee: Mayo Foundation for Medical Education and ResearchInventors: Elliott Richelson, Bernadette Marie Cusack, Yuan-Ping Pang, Daniel J. McCormick, Abdul Fauq, Beth Marie Tyler, Mona Boules
-
Publication number: 20090062212Abstract: Neurotensin analogs selective for neurotensin receptor subtype 2 are described. These include hexapeptides (NT(8-13)) and pentapeptides (NT(9-13)) having a D-3,1-naphthyl-alanine, D-3,2-naphthyl-alanine, an alanine derivative such as cyclohexylalanine, or 1,2,3,4-tetrahydroisoquinoline at position 11. Methods of treating pain by administering these neurotensin analogs are also described.Type: ApplicationFiled: May 7, 2007Publication date: March 5, 2009Inventors: Elliott Richelson, Daniel J. McCormick, Yuan-Ping Pang, Kenneth S. Phillips
-
Publication number: 20080275272Abstract: The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.Type: ApplicationFiled: July 11, 2008Publication date: November 6, 2008Inventors: Elliott Richelson, Paul R. Carlier
-
Publication number: 20080261893Abstract: A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist.Type: ApplicationFiled: March 12, 2008Publication date: October 23, 2008Inventors: Denise BARBUT, Gavril W. Pasternak, Elliott Richelson
-
Publication number: 20080200556Abstract: The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.Type: ApplicationFiled: June 7, 2005Publication date: August 21, 2008Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Elliott Richelson, Paul R. Carlier
-
Publication number: 20080096823Abstract: This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist in combination with an opioid receptor agonist also are provided.Type: ApplicationFiled: February 23, 2007Publication date: April 24, 2008Inventors: Denise Barbut, Elliott Richelson
-
Publication number: 20070197662Abstract: The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.Type: ApplicationFiled: March 30, 2007Publication date: August 23, 2007Inventors: Elliott Richelson, Paul Carlier
-
Publication number: 20070173458Abstract: The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.Type: ApplicationFiled: June 14, 2006Publication date: July 26, 2007Inventors: Elliott Richelson, Bernadette Cusack, Yuan-Ping Pang, Daniel McCormick, Abdul Fauq, Beth Tyler, Mona Boules
-
Patent number: 7214826Abstract: The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.Type: GrantFiled: May 25, 2005Date of Patent: May 8, 2007Assignees: Mayo Foundation for Medical Education and Research, Virginia Tech Intellectual Properties, Inc.Inventors: Elliott Richelson, Paul R. Carlier
-
Patent number: 7098307Abstract: The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.Type: GrantFiled: July 8, 2005Date of Patent: August 29, 2006Assignee: Mayo Foundation for Medical Education and ResearchInventors: Elliott Richelson, Bernadette Marie Cusack, Yuan-Ping Pang, Daniel J. McCormick, Abdul Fauq, Beth Marie Tyler, Mona Boules
-
Publication number: 20060189536Abstract: The invention provides methods and materials for treating the effects of nicotine. In particular, the invention provides methods that involve administering a neurotensin receptor (NTR) agonist to a mammal that has been exposed to nicotine. The NTR agonist typically is administered in an amount effective to diminish or abolish the effects that nicotine has on the treated mammal. NTR agonists that can be used in methods of the invention include neurotensin (NT) polypeptide analogs such as NT69L. The invention also provides compositions containing an NTR agonist in combination with other agents used to help overcome nicotine effects such as sensitization and dependence. The compositions provided herein can be used to treat the effects of nicotine, including hyperactivity, hypothermia, respiratory distress, and hypertension.Type: ApplicationFiled: May 2, 2006Publication date: August 24, 2006Inventors: Elliott Richelson, Paul Fredrickson, Mona Boules
-
Patent number: 7087575Abstract: The invention provides methods and materials for treating the effects of nicotine. In particular, the invention provides methods that involve administering a neurotensin receptor (NTR) agonist to a mammal that has been exposed to nicotine. The NTR agonist typically is administered in an amount effective to diminish or abolish the effects that nicotine has on the treated mammal. NTR agonists that can be used in methods of the invention include neurotensin (NT) polypeptide analogs such as NT69L. The invention also provides compositions containing an NTR agonist in combination with other agents used to help overcome nicotine effects such as sensitization and dependence. The compositions provided herein can be used to treat the effects of nicotine, including hyperactivity, hypothermia, respiratory distress, and hypertension.Type: GrantFiled: July 18, 2002Date of Patent: August 8, 2006Assignee: Mayo Foundation for Medical Education and ResearchInventors: Elliott Richelson, Paul Fredrickson, Mona Boules
-
Patent number: 6989270Abstract: The invention involves methods and materials for extracellularly administering PNA oligomers to living cells. Specifically, the invention provides methods and materials of treating living cells with PNA oligomers such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. In addition, the invention provides methods and materials for orally administering PNA oligomers to animals such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. The invention also provides sense and antisense PNA oligomers that modulate transcription and translation, respectively. The invention also provides mismatch PNA oligomers that modulate the degree of an engendered biological response. In addition, the invention provides methods and materials for detecting PNA oligomers within a biological sample collected from an animal.Type: GrantFiled: October 8, 1998Date of Patent: January 24, 2006Assignee: Mayo Foundation for Medical Education and ResearchInventors: Elliott Richelson, Beth Marie Tyler, Bernadette Marie Cusack, Christopher Lee Douglas, Karen Jansen
-
Publication number: 20050272661Abstract: The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.Type: ApplicationFiled: July 8, 2005Publication date: December 8, 2005Inventors: Elliott Richelson, Bernadette Cusack, Yuan-Ping Pang, Daniel McCormick, Abdul Fauq, Beth Tyler, Mona Boules
-
Publication number: 20050215647Abstract: The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.Type: ApplicationFiled: May 25, 2005Publication date: September 29, 2005Inventors: Elliott Richelson, Paul Carlier
-
Patent number: 6921805Abstract: The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.Type: GrantFiled: June 1, 2004Date of Patent: July 26, 2005Assignee: Mayo Foundation for Medical Education and ResearchInventors: Elliott Richelson, Bernadette Marie Cusack, Yuan-Ping Pang, Daniel J. McCormick, Abdul Fauq, Beth Marie Tyler, Mona Boules
-
Patent number: 6914080Abstract: The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.Type: GrantFiled: January 12, 2004Date of Patent: July 5, 2005Assignees: Mayo Foundation for Medical Education and Research, Virginia Tech Intellectual Properties, Inc.Inventors: Elliott Richelson, Paul R. Carlier
-
Publication number: 20040224889Abstract: The invention involves methods and materials for extracellularly administering PNA oligomers to living cells. Specifically, the invention provides methods and materials of treating living cells with PNA oligomers such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. In addition, the invention provides methods and materials for orally administering PNA oligomers to animals such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. The invention also provides sense and antisense PNA oligomers that modulate transcription and translation, respectively. The invention also provides mismatch PNA oligomers that modulate the degree of an engendered biological response. In addition, the invention provides methods and materials for detecting PNA oligomers within a biological sample collected from an animal.Type: ApplicationFiled: March 12, 2004Publication date: November 11, 2004Applicant: Mayo Foundation for Medical Education and Research, a Minnesota corporationInventors: Elliott Richelson, Beth Marie Tyler, Daniel J. McCormick, Bernadette Marie Cusack, Clark V. Hoshall, Christopher Lee Douglas, Karen Jansen
-
Publication number: 20040220108Abstract: The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.Type: ApplicationFiled: June 1, 2004Publication date: November 4, 2004Applicant: Mayo Foundation for Medical Education and Research, a Minnesota corporationInventors: Elliott Richelson, Bernadette Marie Cusack, Yuan-Ping Pang, Daniel J. McCormick, Abdul Fauq, Beth Marie Tyler, Mona Boules